Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1);The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL

Journal of Neurology

Volumn 256, Issue 3, 2009, Pages 405-415

  Hutchinson, M ^a   Kappos, L ^b   Calabresi, P A ^c   Confavreux, C ^d   Giovannoni, G ^e   Galetta, S L ^f   Havrdova, E ^g   Lublin, F D ^h   Miller, D H ^e   O'Connor, P W ⁱ   Phillips, J T ^j   Polman, C H ^k   Radue, E W ^b   Rudick, R A ^l   Stuart, W H ^m   Wajgt, A ⁿ   Weinstock Guttman, B ^o   Wynn, D R ^p   Lynn, F ^q   Panzara, M A ^q  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HÔPITAL NEUROLOGIQUE   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g CHARLES UNIVERSITY   (Czech Republic)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j Multiple Sclerosis Center at Texas Neurology   (United States)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l LERNER RESEARCH INSTITUTE   (United States)

^m MS Center of Atlanta   (United States)

ⁿ MEDICAL UNIVERSITY OF SILESIA   (Poland)

^o JACOBS NEUROLOGICAL INSTITUTE   (United States)

^p Multiple Sclerosis Center   (United States)

^q BIOGEN   (United States)

more..

Author keywords

Highly active relapsing multiple sclerosis; Interferon beta 1a; Multiple sclerosis; Natalizumab; Subgroup analysis

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; NATALIZUMAB; PLACEBO;

ADULT; ANAMNESIS; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE;

EID: 67349250932     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5183-6     Document Type: Erratum

References (32)

1. ffrench-Constant 1994 Lancet 343 271
2. Elices 1990 Cell 60 577
3. Carlos 1990 Blood 76 965
4. Baron 1993 J Exp Med 177 57
5. Yednock 1992 Nature 356 63
6. Miller 2003 N Engl J Med 348 15
7. Tubridy 1999 Neurology 53 466
8. O'Connor 2004 Neurology 62 2038
9. Polman 2006 N Engl J Med 354 899
10. Rudick 2006 N Engl J Med 354 911
11. Lucchinetti 2000 Ann Neurol 47 707
12. McDonald 2001 Ann Neurol 50 121
13. Kurtzke 1983 Neurology 33 1444
14. Scott 2000 Neurology 55 689
15. Losseff NA, Miller DH, Kidd D, Thompson AJ. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis - preliminary results. Mult Scler 7:23-25
16. Brex 2002 N Engl J Med 346 158
17. Confavreux 2003 Brain 126 770
18. Wang 2007 N Eng J Med 357 2189
19. Tremlett 2008 Mult Scler 14 314
20. Scott 2003 Mult Scler 9 289
21. Weinshenker 1989 Brain 112 1419
22. O'Connor 2005 Mult Scler 11 568
23. European Agency for the Evaluation of Medicinal Products (2006) TYSABRIR (natalizumab) [summary of product characteristics]
24. Jeffery 2002 J Neurol Sci 197 1
25. Trapp 1999 Curr Opin Neurol 12 295
26. Jacobs 1996 Ann Neurol 39 285
27. Johnson 1995 Neurology 45 1268
28. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised doubleblind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
29. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 43:655-661
30. Rio 2005 Mult Scler 11 306
31. O'Rourke 2005 Mult Scler 11 46
32. ® (natalizumab) prescribing information. Cambridge, MA: Biogen Idec Inc.; 2008